{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T20:36:48Z","timestamp":1774903008583,"version":"3.50.1"},"reference-count":33,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,6]]},"DOI":"10.18632\/oncotarget.16731","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T12:22:31Z","timestamp":1490962951000},"page":"37594-37604","source":"Crossref","is-referenced-by-count":14,"title":["Homoharringtonine suppresses imatinib resistance via the Bcl-6\/p53 pathway in chronic myeloid leukemia cell lines"],"prefix":"10.18632","volume":"8","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoye","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxian","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huai\u2019an First People's Hospital, Nanjing Medical University, Huai\u2019an, 223300, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Melo","year":"2003","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.18632\/oncotarget.2278","article-title":"Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy","volume":"5","author":"\u0141os","year":"2014","journal-title":"Oncotarget"},{"key":"3","doi-asserted-by":"publisher","first-page":"66287","DOI":"10.18632\/oncotarget.11507","article-title":"The BCR-ABL\/NF-\u03baB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias","volume":"7","author":"Morotti","year":"2016","journal-title":"Oncotarget"},{"key":"4","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1038\/ncomms9039","article-title":"Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells","volume":"6","author":"Takihara","year":"2015","journal-title":"Nat Commun"},{"key":"5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Kantarjian","year":"2014","journal-title":"Am J Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Talpaz","year":"2003","journal-title":"Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Reiffers","year":"2008","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Wehrle","year":"2010","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Cortes","year":"2009","journal-title":"Cancer Control"},{"key":"11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7150\/ijms.14989","article-title":"EphB4\/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins","volume":"13","author":"Liu","year":"2016","journal-title":"Int J Med Sci"},{"key":"12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.13801","article-title":"Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib","volume":"172","author":"Lipton","year":"2016","journal-title":"Br J Haematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/OTT.S3993","article-title":"Targeted treatment of chronic myeloid leukemia: role of imatinib","volume":"2","author":"Ramanarayanan","year":"2009","journal-title":"Onco Targets Ther"},{"key":"14","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Turner","year":"2012","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1073\/pnas.93.14.6947","article-title":"BCL-6, a POZ\/zinc-finger protein, is a sequence-specific transcriptional repressor","volume":"93","author":"Dalla-Favera","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MOH.0b013e328302c7df","article-title":"B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma","volume":"15","author":"Melnick","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.onc.1206152","article-title":"Ambivalent role of BCL6 in cell survival and transformation","volume":"22","author":"Albagli-Curiel","year":"2003","journal-title":"Oncogene"},{"key":"19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10688","article-title":"FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas","volume":"481","author":"Pagano","year":"2012","journal-title":"Nature"},{"key":"20","first-page":"231","article-title":"[State of chromosome 3q27 and different subtypes of diffuse large B-cell lymphoma and their prognostic correlation]. [Article in Chinese]","volume":"38","author":"Bai","year":"2009","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"21","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/sj.leu.2402707","article-title":"Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics","volume":"16","author":"Bastard","year":"2002","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Dalla-Favera","year":"2004","journal-title":"Nature"},{"key":"23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","article-title":"Homoharringtonine: history, current research, and future direction","volume":"92","author":"O\u2019Brien","year":"2001","journal-title":"Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","article-title":"U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome","volume":"389","author":"Steitz","year":"2009","journal-title":"J Mol Biol"},{"key":"25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","article-title":"Homoharringtonine\/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Holyoake","year":"2011","journal-title":"J Exp Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Ye","year":"2011","journal-title":"J Exp Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Hofmann","year":"2011","journal-title":"Nature"},{"key":"29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","article-title":"The biology of human lymphoid malignancies revealed by gene expression profiling","volume":"87","author":"Dave","year":"2005","journal-title":"Adv Immunol"},{"key":"30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Levine","year":"2000","journal-title":"Nature"},{"key":"31","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3892\/ol.2016.4313","article-title":"MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6","volume":"11","author":"Wei","year":"2016","journal-title":"Oncol Lett"},{"key":"32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1471-2407-14-418","article-title":"B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells","volume":"14","author":"Wu","year":"2014","journal-title":"BMC Cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Xu","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T19:34:29Z","timestamp":1589139269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,6,6]]}},"alternative-id":["16731","28410239"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16731","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}